ONL Therapeutics

[ONL Therapeutics @ONLTherapeutics]

The fruits of a successful collaboration! Our work with our excellent academic friends just published. Congrats to all the contributors and thanks for all the great work! https://t.co/S24yIiKQCc

[ONL Therapeutics @ONLTherapeutics]

We're excited to announce the closing of the first tranche of our Series C! Thanks to all of our investors and our great team for reaching this milestone!
https://t.co/2g0VjDJ77B

[ONL Therapeutics @ONLTherapeutics]

Exciting news! We're looking forward to getting the Phase 2 study started!
https://t.co/PUS2HOYGWA

[David Esposito @D_A_Esposito]

Just finished a great OIS XII 2022 Meeting. So grateful for the OIS team for putting on a great event. Also thankful for the hard work of the ONL team and the VCs and investment bankers in attendance that awarded @ONLTherapeutics the 2022 Ophthalmology Innovation Award! Thank you

[David Esposito @D_A_Esposito]

We are excited to be among the lineup of presenters during OIS XII on December 2-3, at the Hard Rock San Diego. We hope to see you there! https://t.co/ZmMsFo5JfO @ONLTherapeutics

[David Esposito @D_A_Esposito]

It has been a few great days in Melbourne AUS visiting our study sites and witnessing first-hand the hard work of our partners in the clinics. I want to thank Professor Robyn Guymer (CERA) for a great talk on Geography Atrophy to many clinicians in the city. @ONLTherapeutics

[David Esposito @D_A_Esposito]

Just finishing up time with our clinical teams in Melbourne AUS. I am grateful for the courage & sacrifice patients are making when they participate in our trials. To say “yes” to a First-in-Human Phase 1 study is a courageous decision. Thank you to our patients.@ONLTherapeutics

[David Esposito @D_A_Esposito]

Great to visit our hard working clinical study sites in New Zealand (Christchuch, Wellington, and Auckland) #ONL Therapeutics. Thanks for your hard work and commitment. I needed to double strap the pack to get the work done. #somethingsneverchange. @ONLTherapeutics

[ONL Therapeutics @ONLTherapeutics]

We're keeping the momentum going! We're thrilled to announce that Lindsay Godsey is joining the team as our Director of Clinical Operations! Welcome to the team, Lindsay! https://t.co/XzDreyFGjF

[ONL Therapeutics @ONLTherapeutics]

The team is growing! We're thrilled to announce that Sushanta Mallick is our new Chief Development Officer. We're excited that he's joined us on our mission to protect the vision of patients with retinal diseases!
https://t.co/DgAVs19Mjk

[Andrew Kocab @CuriousKocab]

Our review article was just published in the Journal of Clinical Medicine! We describe the role of Fas signaling in AMD progression (and sneak in some original data). Big thanks to my co-authors for their valuable contributions to this work! https://t.co/0S8zaSZ1j6

[ONL Therapeutics @ONLTherapeutics]

We just closed on our second tranche of our Series B financing! Great effort by the team, and we look forward to continuing to advance our development efforts to protect the vision of patients with retinal disease.
https://t.co/RepYjwpsRV

[Andrew Kocab @CuriousKocab]

New blog post on how @USDA scientist @LabSummers is researching how to keep our pork supply healthy and efficient. The key? Pig poop. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog!
https://t.co/tC6fdyyK7Z

[Andrew Kocab @CuriousKocab]

New blog post highlighting the vaccine technology being developed by Iaso Therapeutics. Cool platform that uses bacteriophage to make better vaccines. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog! https://t.co/8zzmT9LdIC

[Andrew Kocab @CuriousKocab]

New blog post highlighting Zack Abbott's path to create @ZBioticsCompany and the company's genetically engineered probiotic. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog! https://t.co/XmRkXKT14L

[ONL Therapeutics @ONLTherapeutics]

We are pleased to welcome Amanda Maciel to the ONL team as Manager of Accounting & Financial Reporting. Welcome to ONL, Amanda!

[Andrew Kocab @CuriousKocab]

My blog's Esposito Trilogy on biotech fundraising & @ONLTherapeutics is complete! Thanks to David Esposito for all of the lessons. Thanks @QIAGEN and @QIAtodd_MI for sponsoring the blog! https://t.co/D4XdPjMrYX

[Andrew Kocab @CuriousKocab]

Another blog post on David Esposito's approach to fundraising, describing how @ONLTherapeutics told its story to investors and refined it along the way. Thanks to @QIAGEN and @QIAtodd_MI for sponsoring the blog! https://t.co/KYNyrPl1My

[Andrew Kocab @CuriousKocab]

New blog post on how David Esposito, CEO of @ONLTherapeutics, approaches fundraising. Thanks to @QIAGEN and @QIAtodd_MI for sponsoring the blog!
https://t.co/J1bN6gnJCE

[Andrew Kocab @CuriousKocab]

Welcome to the @ONLTherapeutics Team, @cchangmba!
https://t.co/LuhtiwwQGa